Neurocrine Biosciences, Inc. (NBIX) key performance indicators and operating metrics (10 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Non-GAAP Diluted Earnings per Share | 1.94 USD_per_share | FY2026-Q1 |
| Non-GAAP Net Income | 200.5M | FY2026-Q1 |
| Net Product Sales | 811M | FY2026-Q1 |
| Ingrezza Net Product Sales | 656.9M | FY2026-Q1 |
| Crenessity Net Product Sales | 153.3M | FY2026-Q1 |
| Crenessity Reimbursement Coverage of Dispensed Prescriptions | 80.00 percent | FY2026-Q1 |
| Other Net Product Sales | 12.7M | FY2025-Q4 |
| Crenessity New Patient Enrollment Start Forms | 431.00 | FY2025-Q4 |
| Non-GAAP Research and Development Expense | 228M | FY2025-Q3 |
| Non-GAAP Selling and General Administrative Expense | 259.4M | FY2025-Q3 |
Back to NBIX overview · NBIX earnings · NBIX holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.